Marvel Biosciences has chosen CMAX Clinical Research in Australia as the site for its Phase I clinical trial of MB-204, a drug candidate targeting autism spectrum disorder and related neurodevelopmental conditions. This marks a key step toward first-in-human testing, following promising preclinical results in mouse models of Rett syndrome, Fragile X syndrome, and autism. The Phase I trial will assess safety, tolerability, and pharmacokinetics, with plans for further studies pending regulatory approval. This progress highlights Marvel's commitment to developing novel treatments for neurological disorders.
Marvel Biosciences' advancement toward first-in-human testing of MB-204 is noted here with Pluang's health sector market context. As of Oct 19, 2026 17:11 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 69 rose and 45 fell. Notable movers include Cytokinetics Inc (CYTK) at USD 63.50 with a 1-day change of +2.50% and a typical hold time of 20 days, Heron Therapeutics Inc (HRTX) at USD 0.37 with +2.49% change and 36 days hold, and Moderna, Inc. (MRNA) at USD 212.60 with a -2.48% change and 59 days hold time.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
